BRIUMVI (Accelagen Pty Ltd)
Product name
BRIUMVI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
101 (255 working days)
Active ingredients
ublituximab
Registration type
NCE/ NBE
Indication
BRIUMVI is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.